Capricor Therapeutics Inc (CAPR)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 231
- Market Cap
- $243M
About Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
SentiSense also tracks daily options readings for Capricor Therapeutics Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Capricor Therapeutics Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.